shutterstock_1349461175_pavel_kapysh
Pavel Kapysh / Shutterstock.com
14 November 2019Big PharmaSaman Javed

Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute

Seattle Genetics has asked the American Arbitration Association (AAA) to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
2 April 2019   Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.
Americas
2 February 2018   Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
Americas
12 February 2020   American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.

More on this story

Big Pharma
2 April 2019   Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.
Americas
2 February 2018   Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
Americas
12 February 2020   American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.

More on this story

Big Pharma
2 April 2019   Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.
Americas
2 February 2018   Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
Americas
12 February 2020   American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.